Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Nahon

Showing results (11-20 of 205) with videos related to

Pageof 21
Sort By:
Liver International : Official Journal of the International Association for the Study of the Liver|March 15, 2022
Atezolizumab and bevacizumab for HCC in the real worldSu Pin Choo, Pierre Nahon
JHEP Reports : Innovation in Hepatology|February 11, 2020
Management of patients with pre-therapeutic advanced liver fibrosis following HCV eradicationPierre Nahon, Nathalie Ganne-Carrié
Journal of Hepatology|August 12, 2014
Genetic predisposition to hepatocellular carcinoma in alcoholic cirrhosis: the NCAN-PNPLA3-lipid connection?Jean-Charles Nault, Pierre Nahon
JHEP Reports : Innovation in Hepatology|July 26, 2021
HCC risk prediction using biomarkers in non-cirrhotic patients following HCV eradication: Reassuring the patient or the doctor?Charlotte E Costentin, Pierre Nahon
Liver International : Official Journal of the International Association for the Study of the Liver|March 16, 2017
Constitutional and functional genetics of human alcohol-related hepatocellular carcinomaPierre Nahon, Jean-Charles Nault
Journal of Hepatology|December 22, 2024
Differences between hepatocellular carcinoma caused by alcohol and other aetiologiesNathalie Ganne-Carrié, Pierre Nahon
Journal of Hepatology|September 20, 2025
Reply to: "Male-to-female ratios in the risk of hepatocellular carcinoma: A nationwide study of Danish patients with viral or non-viral cirrhosis": Advocating for scalable etiology-agnostic HCC risk models for personalized HCC surveillancePierre Nahon, Nathalie Ganne-Carrié
Gastroenterology|March 31, 2019
Can We Move on From the Discussion of Direct Antiviral Agents and Risk of Hepatocellular Carcinoma Recurrence?Jean-Charles Nault, Pierre Nahon
Hepatology (Baltimore, Md.)|March 10, 2023
Screening of liver cancer with abbreviated MRIMaxime Ronot, Pierre Nahon, Jordi Rimola
Hepatology (Baltimore, Md.)|March 21, 2017
ReplyPierre Nahon, Olivier Seror, Isabelle Durand-Zaleski
Pageof 21

Showing results (11-20 of 205) with videos related to

Sort By:
Pageof 21
Liver International : Official Journal of the International Association for the Study of the Liver|March 15, 2022
Atezolizumab and bevacizumab for HCC in the real worldSu Pin Choo, Pierre Nahon
JHEP Reports : Innovation in Hepatology|February 11, 2020
Management of patients with pre-therapeutic advanced liver fibrosis following HCV eradicationPierre Nahon, Nathalie Ganne-Carrié
Journal of Hepatology|August 12, 2014
Genetic predisposition to hepatocellular carcinoma in alcoholic cirrhosis: the NCAN-PNPLA3-lipid connection?Jean-Charles Nault, Pierre Nahon
JHEP Reports : Innovation in Hepatology|July 26, 2021
HCC risk prediction using biomarkers in non-cirrhotic patients following HCV eradication: Reassuring the patient or the doctor?Charlotte E Costentin, Pierre Nahon
Liver International : Official Journal of the International Association for the Study of the Liver|March 16, 2017
Constitutional and functional genetics of human alcohol-related hepatocellular carcinomaPierre Nahon, Jean-Charles Nault
Journal of Hepatology|December 22, 2024
Differences between hepatocellular carcinoma caused by alcohol and other aetiologiesNathalie Ganne-Carrié, Pierre Nahon
Journal of Hepatology|September 20, 2025
Reply to: "Male-to-female ratios in the risk of hepatocellular carcinoma: A nationwide study of Danish patients with viral or non-viral cirrhosis": Advocating for scalable etiology-agnostic HCC risk models for personalized HCC surveillancePierre Nahon, Nathalie Ganne-Carrié
Gastroenterology|March 31, 2019
Can We Move on From the Discussion of Direct Antiviral Agents and Risk of Hepatocellular Carcinoma Recurrence?Jean-Charles Nault, Pierre Nahon
Hepatology (Baltimore, Md.)|March 10, 2023
Screening of liver cancer with abbreviated MRIMaxime Ronot, Pierre Nahon, Jordi Rimola
Hepatology (Baltimore, Md.)|March 21, 2017
ReplyPierre Nahon, Olivier Seror, Isabelle Durand-Zaleski
Pageof 21